Posted by Michael Wonder on 13 Dec 2023
Hutchmed announces continued inclusion of Elunate (fruquintinib) and Sulanda (surufatinib) in the National Reimbursement Drug List in China at current terms
12 December 2023 - Hutchmed today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration, on 1 January 2024 the updated National Reimbursement Drug List will continue to include Elunate (fruquintinib) and Sulanda (surufatinib) at the same terms as the current two year agreement.
Elunate was first included in the NRDL on 1 January 2020 for the treatment of metastatic colorectal cancer.
Sulanda was first included in the NRDL on 1 January 2022 for the treatment of non-pancreatic and pancreatic neuroendocrine tumours.
